Day One Biopharmaceuticals (DAWN) Equity Average (2022 - 2025)
Historic Equity Average for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $455.9 million.
- Day One Biopharmaceuticals' Equity Average rose 574.21% to $455.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $455.9 million, marking a year-over-year increase of 574.21%. This contributed to the annual value of $424.6 million for FY2024, which is 2515.73% up from last year.
- Latest data reveals that Day One Biopharmaceuticals reported Equity Average of $455.9 million as of Q3 2025, which was up 574.21% from $470.2 million recorded in Q2 2025.
- In the past 5 years, Day One Biopharmaceuticals' Equity Average registered a high of $529.1 million during Q4 2024, and its lowest value of $301.8 million during Q2 2024.
- Its 4-year average for Equity Average is $393.3 million, with a median of $372.5 million in 2022.
- In the last 5 years, Day One Biopharmaceuticals' Equity Average crashed by 1692.19% in 2024 and then soared by 5580.59% in 2025.
- Day One Biopharmaceuticals' Equity Average (Quarter) stood at $347.6 million in 2022, then increased by 5.91% to $368.1 million in 2023, then skyrocketed by 43.75% to $529.1 million in 2024, then dropped by 13.85% to $455.9 million in 2025.
- Its Equity Average was $455.9 million in Q3 2025, compared to $470.2 million in Q2 2025 and $491.1 million in Q1 2025.